12AEntitlement to botulinum toxin pharmaceutical benefits for treatment of urinary incontinence due to neurogenic detrusor overactivity, as demonstrated by urodynamic study etc

12A Entitlement to botulinum toxin pharmaceutical benefits for treatment of urinary incontinence due to neurogenic detrusor overactivity, as demonstrated by urodynamic study etc

(1) This section applies to eligible patients receiving treatment of urinary continence due to neurogenic detrusor overactivity, as demonstrated by urodynamic study in patients who have (a) multiple sclerosis, or (b) a spinal cord injury, or (c) who are 18 years or older and have spina bifida. (2) A person mentioned in subsection (1) is not eligible to receive a botulinum toxin pharmaceutical benefit under this Special Arrangement unless: (a) the condition is inadequately controlled by anti‑cholinergic therapy, (b) the person has experienced at least 14 episodes of urinary incontinence per week prior to commencement of treatment with a botulinum toxin pharmaceutical benefit, and (c) the person is willing and able to self‑catheterise. (3) A person mentioned in subsection (1) is not eligible to receive a botulinum toxin pharmaceutical benefit under this Special Arrangement if the person does not achieve a 50% or greater reduction from baseline in urinary incontinence episodes 6‑12 weeks after the first treatment.